文献速递贫血与红细胞疾病

DNMT1天然突变通过表观遗传去抑制γ-珠蛋白基因升高β-地中海贫血胎儿血红蛋白水平

A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia.
PubMed 文献 · Blood · 2021-01-01

研究系统分析1142例β-地中海贫血患者DNMT1变异与表型关联,鉴定出BAH1结构域新错义突变c.2633G>A(S878F)。功能实验表明该突变消除DNMT1磷酸化、降低稳定性和催化活性,减弱与BCL11A、GATA1、HDAC1/2互作及γ-珠蛋白启动子招募,导致γ-珠蛋白表观去抑制和HbF升高,且效应呈异细胞性;CRISPR-Cas9引入该突变可重现γ-珠蛋白再激活。

要点

  • DNMT1 S878F突变与β-地中海贫血HbF升高相关。
  • 突变通过减弱DNMT1与BCL11A/GATA1/HDAC1/2互作去抑制γ-珠蛋白。
  • 该突变为β-血红蛋白病潜在治疗靶点。

核心结论

  • DNMT1天然S878F突变是HbF合成的新型调控因子,并可能成为β-血红蛋白病的新治疗靶点。

研究设计与样本

  • 系统分析1142例β-地中海贫血患者DNMT1变异与表型的关联。
  • 在患者CD34+细胞和工程化HuDEP-2突变细胞中进行功能鉴定。
  • 利用CRISPR-Cas9将S878F突变引入红系细胞以验证γ-珠蛋白再激活。

主要发现

  • 鉴定出DNMT1 BAH1结构域新错义突变c.2633G>A(S878F)。
  • S878F突变消除DNMT1磷酸化,导致稳定性降低和催化活性丧失。
  • S878F突变减弱DNMT1与BCL11A、GATA1和HDAC1/2的互作,并减少DNMT1向γ-珠蛋白(HBG)启动子的招募。
  • S878F突变导致γ-珠蛋白表达的表观遗传去抑制,且对HbF升高的效应呈异细胞性。
  • CRISPR-Cas9引入S878F突变可重现γ-珠蛋白再激活。

临床怎么用

  • S878F突变可作为β-血红蛋白病升高HbF的潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DNA methyltransferase 1 (DNMT1) is a major epigenetic regulator of the formation of large macromolecular complexes that repress human γ-globin expression by maintaining DNA methylation. However, very little is known about the association of DNMT1 variants with β-thalassemia phenotypes. We systematically investigated associations between variants in DNMT1 and phenotypes in 1142 β-thalassemia subjects and identified a novel missense mutation (c.2633G>A, S878F) in the DNMT1 bromo-adjacent homology-1 (BAH1) domain. We functionally characterized this mutation in CD34+ cells from patients and engineered HuDEP-2 mutant cells. Our results demonstrate that DNMT1 phosphorylation is abrogated by substituting serine with phenylalanine at position 878, resulting in lower stability and catalytic activity loss. S878F mutation also attenuated DNMT1 interactions with BCL11A, GATA1, and HDAC1/2, and reduced recruitment of DNMT1 to the γ-globin (HBG) promoters, leading to epigenetic derepression of γ-globin expression. By analyzing the F-cell pattern, we demonstrated that the effect of DNMT1 mutation on increased fetal hemoglobin (HbF) is heterocellular. Furthermore, introduction of S878F mutation into erythroid cells by clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) recapitulated γ-globin reactivation. Thus, the natural S878F DNMT1 mutation is a novel modulator of HbF synthesis and represents a potential new therapeutic target for β-hemoglobinopathies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gong Y, Zhang X, Zhang Q, et al. A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the γ-globin gene in β-thalassemia. Blood. 2021. PMID: 33227819. doi:10.1182/blood.2020006425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。